|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Capitalization1 |
215 897 | 252 318 | 216 827 | 204 605 | 331 440 | 279 215 | - | - |
Enterprise Value (EV)1 |
239 396 | 275 225 | 259 147 | 232 220 | 338 807 | 267 693 | 258 489 | 240 184 |
P/E ratio |
10,3x | 23,3x | 13,7x | 21,5x | 15,3x | 8,83x | 11,6x | 14,5x |
Yield |
3,53% | 3,12% | 3,68% | 4,13% | 2,64% | 3,26% | 3,36% | 3,44% |
Capitalization / Revenue |
4,11x | 4,70x | 4,19x | 4,88x | 4,08x | 2,75x | 3,61x | 4,14x |
EV / Revenue |
4,56x | 5,13x | 5,01x | 5,54x | 4,17x | 2,63x | 3,34x | 3,56x |
EV / EBITDA |
11,3x | 12,6x | 12,3x | 13,0x | 13,3x | 5,80x | 6,99x | 8,18x |
Price to Book |
3,04x | 3,94x | 3,43x | 3,24x | 4,30x | 2,82x | 2,51x | 2,38x |
Nbr of stocks (in thousands) |
5 960 707 | 5 780 475 | 5 534 122 | 5 558 397 | 5 612 867 | 5 612 352 | - | - |
Reference price (USD) |
36,2 | 43,7 | 39,2 | 36,8 | 59,1 | 49,8 | 49,8 | 49,8 |
Announcement Date |
01/30/2018 | 01/29/2019 | 01/28/2020 | 02/02/2021 | 02/08/2022 | - | - | - |
1 USD in Million |
|
|
Income Statement Evolution (Annual data) |
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Net sales1 |
52 546 | 53 647 | 51 750 | 41 908 | 81 288 | 101 648 | 77 405 | 67 497 |
EBITDA1 |
21 172 | 21 814 | 21 097 | 17 801 | 25 426 | 46 173 | 36 976 | 29 369 |
Operating profit (EBIT)1 |
19 468 | 20 042 | 19 420 | 13 024 | 20 235 | 41 328 | 29 711 | 25 151 |
Operating Margin |
37,0% | 37,4% | 37,5% | 31,1% | 24,9% | 40,7% | 38,4% | 37,3% |
Pre-Tax Profit (EBT)1 |
12 305 | 11 885 | 17 682 | 7 497 | 24 311 | 37 694 | 26 133 | 19 798 |
Net income1 |
21 308 | 11 153 | 16 273 | 9 616 | 21 979 | 32 675 | 22 879 | 18 138 |
Net margin |
40,6% | 20,8% | 31,4% | 22,9% | 27,0% | 32,1% | 29,6% | 26,9% |
EPS2 |
3,52 | 1,87 | 2,87 | 1,71 | 3,85 | 5,64 | 4,29 | 3,42 |
Dividend per Share2 |
1,28 | 1,36 | 1,44 | 1,52 | 1,56 | 1,62 | 1,67 | 1,71 |
Announcement Date |
01/30/2018 | 01/29/2019 | 01/28/2020 | 02/02/2021 | 02/08/2022 | - | - | - |
1 USD in Million 2 USD |
|
|
Income Statement Evolution (Quarterly data) |
|
Fiscal Period: December
|
2020 Q1 |
2020 Q2 |
2020 Q3 |
2020 Q4 |
2021 Q1 |
2021 Q2 |
2021 Q3 |
2021 Q4 |
2022 Q1 |
2022 Q2 |
2022 Q3 |
2022 Q4 |
2023 Q1 |
2023 Q2 |
2023 Q3 |
Net sales1 |
12 028 | 11 801 | 12 131 | 11 684 | 14 582 | 18 977 | 24 094 | 23 838 | 25 661 | 27 742 | 21 962 | 24 641 | 21 053 | 20 355 | 18 975 |
EBITDA1 |
5 539 | 5 279 | 5 595 | 3 114 | 6 850 | 8 243 | 9 876 | 4 403 | 11 135 | - | 11 733 | 8 050 | - | - | - |
Operating profit (EBIT)1 |
5 135 | 4 791 | 4 333 | 2 068 | 5 624 | 6 746 | 8 516 | 3 126 | 9 948 | 12 408 | 9 361 | 7 969 | 8 348 | - | - |
Operating Margin |
42,7% | 40,6% | 35,7% | 17,7% | 38,6% | 35,5% | 35,3% | 13,1% | 38,8% | 44,7% | 42,6% | 32,3% | 39,7% | - | - |
Pre-Tax Profit (EBT) |
- | - | - | - | - | - | - | - | 9 050 | - | - | - | - | - | - |
Net income1 |
3 401 | - | 2 194 | 594 | 4 877 | 5 563 | 8 146 | 3 393 | 7 864 | 9 906 | 8 020 | 6 639 | - | - | - |
Net margin |
28,3% | - | 18,1% | 5,08% | 33,4% | 29,3% | 33,8% | 14,2% | 30,6% | 35,7% | 36,5% | 26,9% | - | - | - |
EPS2 |
0,61 | - | 0,39 | 0,10 | 0,86 | 0,98 | 1,42 | 0,59 | 1,37 | 1,73 | 1,42 | 1,09 | - | - | - |
Dividend per Share |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date |
04/28/2020 | 07/28/2020 | 10/27/2020 | 02/02/2021 | 05/04/2021 | 07/28/2021 | 11/02/2021 | 02/08/2022 | 05/03/2022 | 07/28/2022 | - | - | - | - | - |
1 USD in Million 2 USD |
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Net Debt1 |
23 499 | 22 907 | 42 320 | 27 615 | 7 367 | - | - | - |
Net Cash position1 |
- | - | - | - | - | 11 522 | 20 726 | 39 030 |
Leverage (Debt / EBITDA) |
1,11x | 1,05x | 2,01x | 1,55x | 0,29x | -0,25x | -0,56x | -1,33x |
Free Cash Flow1 |
14 514 | 13 785 | 10 412 | 12 151 | 29 869 | 35 555 | 27 535 | 23 749 |
ROE (Net Profit / Equities) |
24,6% | 16,6% | 25,7% | 15,2% | 31,3% | 41,3% | 25,6% | 17,9% |
Shareholders' equity1 |
86 671 | 67 357 | 63 275 | 63 180 | 70 220 | 79 182 | 89 204 | 101 162 |
ROA (Net Profit / Asset) |
9,37% | 6,73% | 9,96% | 5,98% | 13,1% | 18,8% | 11,6% | 9,91% |
Assets1 |
227 460 | 165 609 | 163 456 | 160 910 | 167 853 | 174 044 | 197 841 | 183 050 |
Book Value Per Share2 |
11,9 | 11,1 | 11,4 | 11,4 | 13,7 | 17,7 | 19,8 | 20,9 |
Cash Flow per Share2 |
2,72 | 2,65 | 2,22 | 2,56 | 5,71 | 6,62 | 4,93 | 3,84 |
Capex1 |
1 956 | 2 042 | 2 176 | 2 252 | 2 711 | 2 795 | 2 756 | 2 529 |
Capex / Sales |
3,72% | 3,81% | 4,20% | 5,37% | 3,34% | 2,75% | 3,56% | 3,75% |
Announcement Date |
01/30/2018 | 01/29/2019 | 01/28/2020 | 02/02/2021 | 02/08/2022 | - | - | - |
1 USD in Million 2 USD |
|
| |
|
|
Biotech stocks pin bounce back hopes on M&A boost |
Capitalization (USD) |
279 214 502 497 |
Net sales (USD) |
81 288 000 000 |
Number of employees |
79 000 |
Sales / Employee (USD) |
1 028 962 |
Free-Float |
59,0% |
Free-Float capitalization (USD) |
164 613 799 703 |
Avg. Exchange 20 sessions (USD) |
993 594 485 |
Average Daily Capital Traded |
0,36% |
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
|